BTAI
Research Snapshot
Static fundamentals, valuation context, and investor signals for BioXcel Therapeutics, Inc. (BTAI).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-494.6%
ROIC, -8974.3% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
-1.1x
Debt/equity, 0.8x current ratio
Superinvestors
1
Top: Howard Marks (0.0%)
Strengths to research
- Return on equity is strong at 73.2%.
- Debt/equity looks manageable at -1.1x.
- 9 annual periods are available for trend analysis.
Watchouts
- Free cash flow margin is negative at -8974.3%.
- Current ratio is below 1 at 0.8x.
- Valuation multiples are limited or unavailable.
Annual data: 9 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for BTAI.
Grade F
0
/ 100
Financial Charts
No financial data available for BTAI (annual).
1 superinvestors own BTAI
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Howard Marks Oaktree Capital Management | 241,188 | $323,000 | 0.01% | 0.0% |